Noha A Bassiouny

Dr. Noha A Bassiouny

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2023 in Drug Safety
Verified
Journal Article
Open access
PDF file
MSManar A. Serageldin
Manar A. Serageldin
AKamira B. kassem
amira B. kassem
YEYasser El-Kerm
Yasser El-Kerm
MHMAGED WASFY HELMY
MAGED WASFY HELMY
MEMahmoud El-Mas
Mahmoud El-Mas
NBNoha A Bassiouny
Noha A Bassiouny
Background and Objective Breast cancer patients treated with adriamycin-cyclophosphamide plus paclitaxel (AC-T) are often challenged with serious adverse effects for which no effective therapies are available. Here, we investigated whether metformin, an antidiabetic drug with additional pleiotropic effects could favourably offset AC-T induced toxicities. Patients and Methods Seventy non-diabetic breast cancer patients were randomised to receive either AC-T (adriamycin 60 mg/m2 + cyclophosphamide 600 mg/m2 × 4 cycles Q21 days, followed by weekly paclitaxel 80 mg/m2 × 12 cycles) alone or AC-T plus metformin (1700 mg/day). Patients were assessed regularly after each cycle to record the incidence and severity of adverse events based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0. Moreover, baseline echocardiography and ultrasonography were done and repeated after the end of neoadjuvant therapy. Results Addition of metformin to AC-T resulted in significantly less incidence and severity of peripheral neuropathy, oral mucositis, and fatigue (p < 0.05) compared to control arm. Moreover, the left ventricular ejection fraction (LVEF%) in the control arm dropped from a mean of 66.69 ± 4.57 to 62.2 ± 5.22% (p = 0.0004) versus a preserved cardiac function in the metformin arm (64.87 ± 4.84 to 65.94 ± 3.44%, p = 0.2667). Furthermore, fatty liver incidence was significantly lower in metformin compared with control arm (8.33% vs 51.85%, p = 0.001). By contrast, haematological disturbances caused by AC-T were preserved after concurrent metformin administration (p > 0.05). Conclusion Metformin offers a therapeutic opportunity for controlling toxicities caused by neoadjuvant chemotherapy in non-diabetic breast cancer patients. Trial Registration This randomised controlled trial was registered on November 20, 2019 in ClinicalTrials.gov under registration number: NCT04170465.

22 February 2016 in Clinical & Experimental Metastasis
Verified
Journal Article
Closed access
PDF file
SESahar Mohammed El-Haggar
Sahar Mohammed El-Haggar
NENagla A. El-Shitany
Nagla A. El-Shitany
MMMohamed Farouk Mostafa
Mohamed Farouk Mostafa
NBNoha A Bassiouny
Noha A Bassiouny

31 January 2022 in Clinical Breast Cancer
Verified
Journal Article
Closed access
NBNoha A Bassiouny
Noha A Bassiouny
MHMAGED WASFY HELMY
MAGED WASFY HELMY
MHMostafa Alaa Eldin Hassan
Mostafa Alaa Eldin Hassan
GKGehan A. Khedr
Gehan A. Khedr

7 August 2024 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
MSManar A. Serageldin
Manar A. Serageldin
NBNoha A Bassiouny
Noha A Bassiouny
YEYasser El‐Kerm
Yasser El‐Kerm
RARania Aly
Rania Aly
MHMAGED WASFY HELMY
MAGED WASFY HELMY
AKamira B. kassem
amira B. kassem

1 February 2022 in Pharmacy Practice
Verified
Journal Article
Open access
PDF file
OIOsama Ibrahim
Osama Ibrahim
NBNoha A Bassiouny
Noha A Bassiouny
EDEsraa Abdelhameed Dergham
Esraa Abdelhameed Dergham
NMNadia Al Mazrouei
Nadia Al Mazrouei
AMAhmad Z. Al Meslamani
Ahmad Z. Al Meslamani
AKamira B. kassem
amira B. kassem
Background: Although pharmacists are trusted and easily accessible by the public, their role in changing health behaviours related to breast cancer has been rarely investigated. Objective: To investigate the effectiveness of pharmacist-based coaching in improving BC-related health behaviors and knowledge in females, and to measure the comfort level toward this program. Methods: This was a randomized controlled study carried out in community pharmacies in Egypt. Pharmacies included were asked to enroll 240 females into a trial, then equally allocate them into either active or control arms, and provide 12 weekly face-to-face coaching sessions to those assigned to the active arm. Pharmacists were also asked to survey females and fill a standardized data collection form at baseline, in the middle of coaching, at the end of coaching, and three months after coaching. Results: The proportions of doing high physical activity, practicing healthy diet, and practicing breast self-exam three months after the end of coaching programme across the active and control arms were 52.17% versus 17.09% (p=0.002), 62.60% versus 28.20% (p=0.003), and 81.73% versus 23.07% (p=0.005), respectively. The mean scores of knowledge on BC symptoms, risk factors, and detection methods three months after coaching across the active and control arms were 4.10±2.47 versus 2.72±1.19 (p=0.038), 4.25±2.20 versus 3.28±1.48 (p=0.020), and .34±1.80 versus 1.72±0.68 (p=0.001) respectively. While most of the females participated in the active arm were comfortable toward the financial 94.78% and social 88.69% sides of the program, more than one-third (34.78%) of the participants were uncomfortable toward the competency of coaches. Conclusion: Despite the need for some modifications, BC-related health behaviors and knowledge can be improved through pharmacist-based health coaching. Pharmacy Practice is a free full-text journal with a scope on the practice of pharmacy. Pharmacy Practice covers pharmaceutical care, social pharmacy, pharmacy education, process and outcome research, health promotion and education, health informatics, pharmacoepidemiology

10 April 2025 in Inflammopharmacology
Verified
Journal Article
Open access
AGAlaa Refaat Gouda
Alaa Refaat Gouda
NBNoha A Bassiouny
Noha A Bassiouny
Ahmad SalahuddinAhmad Salahuddin
Ahmad Salahuddin
EHEmad Hamdy Hamouda
Emad Hamdy Hamouda
AKamira B. kassem
amira B. kassem
Introduction: Traumatic brain injury (TBI) refers to an impact of the brain within the skull resulting in an altered mental state. The study aim is to determine the effect of a high dose of N-acetylcysteine (NAC) on biochemical and inflammatory markers of neuronal damage and clinical outcomes in patients with moderate to severe TBI. Methods: A randomized open label-controlled trial was conducted on 40 patients with moderate to severe TBI patients presented to the emergency unit within < 24 h since the trauma occurred and randomized into NAC and control groups 20 patients each. Serum samples for evaluation of biomarkers: malondialdehyde (MDA), interleukin-6 (IL-6), neuron-specific enolase (NSE), and S100B were withdrawn at baseline and on day 7. The patients were followed for 7 days and evaluated clinically by the Glasgow Coma Scale (GCS). Results: There was a significant decrease in NSE and MDA levels on day 7 from baseline in NAC group (p < 0.001 and p < 0.001). Also, S100B and IL-6 decreased significantly in NAC group on day 7 from baseline (p = 0.003 and p < 0.001 consequently) compared to control group. Moreover, patients in NAC group showed a significantly shorter length of stay at intensive care unit (ICU) (p = 0.038). There was a significant increase in GCS in NAC group on day 7 from baseline (p = 0.001). Conclusion: Adjunctive early use of high-dose NAC significantly reduced inflammatory and oxidative markers and had neuroprotective effect which may be a novel treatment option for moderate to severe TBI patients. Trial registration: Pactr.org identifier: (PACTR202209548995270) on 14 September 2022.